Edwards Lifesciences Corp (NYSE:EW) VP Donald E. Bobo, Jr. Sells 5,369 Shares of Stock

Edwards Lifesciences Corp (NYSE:EW) VP Donald E. Bobo, Jr. sold 5,369 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $234.37, for a total value of $1,258,332.53. Following the sale, the vice president now directly owns 26,082 shares in the company, valued at $6,112,838.34. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Shares of NYSE EW opened at $234.16 on Friday. Edwards Lifesciences Corp has a twelve month low of $139.64 and a twelve month high of $241.82. The firm has a market cap of $48.47 billion, a P/E ratio of 49.82, a PEG ratio of 2.81 and a beta of 0.82. The company has a 50 day moving average of $226.79 and a 200 day moving average of $203.32. The company has a quick ratio of 2.74, a current ratio of 3.53 and a debt-to-equity ratio of 0.17.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $1.41 earnings per share for the quarter, topping analysts’ consensus estimates of $1.22 by $0.19. Edwards Lifesciences had a net margin of 18.64% and a return on equity of 32.28%. The company had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.04 billion. During the same period in the previous year, the business earned $1.07 EPS. The firm’s revenue for the quarter was up 20.7% on a year-over-year basis. As a group, equities analysts expect that Edwards Lifesciences Corp will post 5.6 earnings per share for the current fiscal year.

Several research firms have weighed in on EW. Canaccord Genuity lifted their price objective on Edwards Lifesciences from $250.00 to $260.00 and gave the company a “buy” rating in a research report on Thursday, October 24th. Morgan Stanley lifted their price objective on Edwards Lifesciences from $228.00 to $248.00 and gave the company an “overweight” rating in a research report on Thursday, October 24th. Zacks Investment Research raised Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $232.00 price objective on the stock in a research report on Thursday, July 25th. Bank of America boosted their price target on Edwards Lifesciences from $225.00 to $250.00 and gave the stock a “buy” rating in a research report on Thursday, October 24th. Finally, Stifel Nicolaus boosted their price target on Edwards Lifesciences from $215.00 to $250.00 and gave the stock a “buy” rating in a research report on Thursday, October 24th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and thirteen have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $237.89.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Bath Savings Trust Co grew its position in shares of Edwards Lifesciences by 7.7% during the 2nd quarter. Bath Savings Trust Co now owns 27,121 shares of the medical research company’s stock valued at $5,010,000 after acquiring an additional 1,949 shares during the period. WINTON GROUP Ltd boosted its holdings in Edwards Lifesciences by 41.1% in the 2nd quarter. WINTON GROUP Ltd now owns 5,744 shares of the medical research company’s stock worth $1,061,000 after buying an additional 1,673 shares during the period. RDA Financial Network boosted its holdings in Edwards Lifesciences by 6.9% in the 2nd quarter. RDA Financial Network now owns 4,313 shares of the medical research company’s stock worth $805,000 after buying an additional 280 shares during the period. New England Research & Management Inc. bought a new position in Edwards Lifesciences in the 2nd quarter worth $323,000. Finally, Harbour Capital Advisors LLC boosted its holdings in Edwards Lifesciences by 0.9% in the 2nd quarter. Harbour Capital Advisors LLC now owns 11,085 shares of the medical research company’s stock worth $2,048,000 after buying an additional 98 shares during the period. Institutional investors own 81.31% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.

Recommended Story: What does earnings per share mean?

Insider Buying and Selling by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.